

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab)
Recombinant Antibody
Catalog # APR10073****Specification**

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Product Information

Application	FC, E, FTA
Primary Accession	P32970
Reactivity	Cynomolgus, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	144.36 KDa

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Additional Information

Target/Specificity
TNFSF7 / CD27L / CD70

Endotoxin
< 0.001EU/ µg,determined by LAL method.

Conjugation
Unconjugated

Expression system
CHO Cell

Format
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Storage
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Protein Information

Name CD70

Synonyms CD27L, CD27LG, TNFSF7

Function
Cytokine which is the ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells.

Cellular Location


Membrane; Single- pass type II membrane protein

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) - Images




Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) is more than 95%, determined by SEC-HPLC.



Immobilized human CD70 FC at 4 µg/mL can bind Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) $EC_{50}=0.08279$ µg/mL



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (cusatuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, $EC_{125}=0.2727$ µg/mL